Clinical Trials on Immunologic Disease

Total 382616 results

Astellas Pharma Inc
Astellas Pharma Taiwan, Inc.

Completed

A Randomized Study to Assess the Safety and Efficacy of Prograf vs Prograf-XL in de Novo Liver Transplant Recipients.

Liver Transplantation | Transplantation Immunology | Host vs Graft Reaction

Taiwan
Regina Elena Cancer Institute

Completed

Approaches and Metrics in Fraily Patients During COVID-19 Era (COMETA)

Frailty | Oncology | Immune Deficiency

Italy
Mayo Clinic

Terminated

Cardiopulmonary Bypass-Induced Lymphocytopenia and the Potential Effects of Protease Inhibitor

Cardiopulmonary Bypass

United States
BriovaRx Infusion Services
Bio Products Laboratory (BPL)

Completed

Monitoring of 5% Treatment Naïve Intravenous Immunoglobulin (IVIg) Primary Immunodeficiency Disease (PIDD) Patients Using the CareExchange® System: A Pilot Study Using 5% Gammaplex® IVIg in the Home Setting

Primary Immunodeficiency Disease (PIDD)

United States
PATH

Not yet recruiting

Developing a Screening Tool for Primary Immunodeficiency Disease (PID) in Pakistan

Primary Immunodeficiency Diseases

Pakistan
Octapharma
Premier Research Group plc

Completed

A Study of NewGam, Human Immunoglobulin 10%, in Patients With Primary Immunodeficiency Diseases

Primary Immunodeficiency Diseases

United States
University Health Network, Toronto
CSL Behring

Completed

Subcutaneous Ig in Allogeneic Stem Cell Transplant Recipients (ScIGalloHCT)

Hypogammaglobulinemia

Canada
University Children's Hospital, Zurich
University Hospital, Geneva; University Children's Hospital Basel

Recruiting

Genetic Study of Immunodeficiency: Search for New Genetic Causes for Primary Immunodeficiencies (GSI)

Immunologic Deficiency Syndromes

Switzerland
Prothya Biosolutions

Completed

Pharmacokinetics and Safety of IVIG Nanogam 100 mg/ml (Nanogam)

Primary Immunodeficiency

Netherlands
Prothya Biosolutions

Completed

Treatment of Deficient Subclass or Anti-polysaccharide Antibody Response (Subklasse)

Infections | IgG Deficiency

Netherlands
Icahn School of Medicine at Mount Sinai

Completed

Randomized Study of Polyethylene-Glycol-Conjugated Interleukin 2 in Patients With Common Variable Immunodeficiency

Common Variable Immunodeficiency
Washington University School of Medicine

Recruiting

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

Hemoglobinopathies | Bone Marrow Failure Syndromes | Metabolic Disorders | Non-malignant Disorders | Severe Sickle Cell Disease | Immunologic Disorders

United States
Qu Biologics Inc.
The National Research Council of Canada Industrial Research Assistance Program

Recruiting

Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults (RESILIENCE)

Immune Deficiency

Canada
Prothya Biosolutions

Completed

Kinetics, Efficacy and Safety of IVIG-L in Hypogammaglobulinemia Patients

Hypogammaglobulinemia

Netherlands
Gazi University

Recruiting

Investigation of the Effects of Pulmonary Rehabilitation in Children With Primary Immunodeficiency

Primary Immunodeficiency

Turkey
Grifols Therapeutics LLC

Completed

A Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Participants and Loading/Maintenance Dosing in Treatment-Naïve Participants With Primary Immunodeficiency

Primary Immunodeficiency

United States
Grifols Therapeutics LLC

Completed

Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

United States, Canada
Octapharma

Completed

The Effect of Subcutaneous Immunoglobulin Gammanorm on the Distribution of IgG Subclasses and on Immunity of Patients With Secondary Immunodeficiency

Secondary Immune Deficiency

France
Ottawa Hospital Research Institute
Octapharma

Unknown

Safety, Tolerability, Patient Satisfaction and Cost of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment

Primary Immunodeficiency Disease | Secondary Immunodeficiency

Canada
Octapharma

Completed

CLINICAL PHASE III STUDY TO MONITOR THE SAFETY, TOLERABILITY AND EFFICACY OF SUBCUTANEOUS HUMAN IMMUNOGLOBULIN (OCTANORM) IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY DISEASES, INCLUDING (BUT NOT LIMITED TO) THOSE WHO HAVE COMPLETED THE SCGAM-01 TRIAL

Primary Immunodeficiency

United States, Canada
Assiut University

Completed

Minipooled-IVIG in Primary Immunodeficiency Disease

Primary Immunodeficiency

Egypt
CSL Behring

Completed

Safety and Tolerability of Higher Infusion Parameters of IgPro20 (Hizentra) in Subjects With Primary Immunodeficiency (PID)

Primary Immunodeficiency

United States, Canada
IMMUNOe Research Centers

Completed

The Benefit of 5% IVIG for Patients With Primary Immunodeficiency Disorders Who Experience Adverse Events on 10% IVIG Preparations

Primary Immunodeficiency
Grifols Therapeutics LLC

Completed

Pharmacokinetics, Safety, and Tolerability of Subcutaneous GAMUNEX-C in Pediatric Subjects With Primary Immunodeficiency (KIDS)

Primary Immunodeficiency

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Immune Regulation in Patients With Common Variable Immunodeficiency and Related Syndromes

CVID | XLA

United States
Universidade Metodista de Piracicaba

Completed

Electromiography Study in the Respiratory Muscle Training in Human Lymphotropic Virus Type 1

HTLV-I Infections

Brazil
Emory University

Completed

Protective Immunity Project 02 (PIP-02)

Immunology | Immunosuppression | Kidney Transplant

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Safety of Belimumab in People With Idiopathic CD4 Lymphopenia and Autoantibodies (Phoebe)

Idiopathic CD4 Lymphopenia

United States
University Hospital, Lille

Completed

Evolution of Interleukin 7, Fat Mass and Metabolic Profile Before and After Transplantation (IL-7tran)

Immunodeficiency Secondary to Organ Transplantation

France
Assistance Publique - Hôpitaux de Paris

Completed

Idiopathic CD4 Lymphocytopenia (Lympho-4)

Idiopathic CD4 Lymphocytopenia

France
University of Maryland, Baltimore

Withdrawn

Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS)

Chronic Rejection of Lung Transplant | Disorder Related to Lung Transplantation | Decreased Immunologic Activity
Novartis Pharmaceuticals

Completed

Study of Efficacy of CDZ173 in Patients With APDS/PASLI

Common Variable Immunodeficiency (CVID), APDS / PASLI

Germany, Russian Federation, Ireland, Italy, United Kingdom, Belarus, Netherlands, Czechia, United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Send-In Sample Collection to Achieve Genetic and Immunologic Characterization of Primary Immunodeficiencies

Primary Immunodeficiency

United States, Turkey, Italy
Prometic Biotherapeutics, Inc.
Atlantic Research Group

Completed

Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%

Primary Immunodeficiency

United States
Grifols Therapeutics LLC

Completed

Efficacy, Pharmacokinetics, Safety, and Tolerability of IGSC 20% in Subjects With Primary Immunodeficiency

Primary Immunodeficiency

Spain, France, Germany, United Kingdom, Australia, Czechia, Hungary, Poland, Sweden
University Hospital, Lille
Shire

Completed

IgG Level in Primary Immunodeficiency Switching From Standard SCIG to Every Other Week HyQvia

Primary Immunodeficiency

France
National Institute of Allergy and Infectious Diseases...

Completed

STA-5326 Meslylate to Treat Gut Inflammation Associated With Common Variable Immunodeficiency

Common Variable Immunodeficiency

United States
ASIS Corporation

Unknown

ASIS for GAMMAGARD in Primary Immunodeficiency (ASISinPI)

Primary Immunodeficiency

United States
National Institute of Allergy and Infectious Diseases...

Recruiting

Genetic Analysis of Immune Disorders

Immunodeficiency | GATA2 | DOK 8 | STAT1 | STAT3

United States
FFF Enterprises
OMRIX Biopharmaceuticals

Completed

A Clinical Study of Intravenous Immunoglobulin (IGIV)

Immunologic Deficiency Syndromes

United States, Canada
Dr Medhat Khafagy

Completed

Etiology of Lymphopenia in Covid19 Infection

Lymphopenia

Egypt
Kedrion S.p.A.

Recruiting

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in Pediatric PID Patients (KIDCARES10) (KIDCARES10)

Primary Immunodeficiency Disease

Italy, United States, Portugal, Hungary, Russian Federation, Slovakia
Kedrion S.p.A.

Completed

Clinical Assessment of Pharmacokinetics, Efficacy, and Safety of 10% IVIg in PID Patients (CARES10)

Primary Immunodeficiency Disease

United States
University Hospital, Montpellier

Completed

Immune Activation in HIV-1 Infected Patients Under AntiRetroviral Treatment (ACTIVIH)

Immune Deficiency | Other Diagnoses, Comorbidities, and Complications | HIV-related Gut Disease - Cause Unknown | Activation of Latent Virus

France
University Hospital, Strasbourg, France

Unknown

Retrospective Non-interventional Analysis of Opportunistic Infections in Immunocompromised and Frail Patients

Immunologic Deficiency Syndromes | Critical Illness | Transplantation | Hematologic Disease | Neoplams

France
Federal Research Institute of Pediatric Hematology...

Recruiting

Evaluation of Subcutaneous Immunoglobulin Product Cutaquig in Terms of Safety and Efficacy in the Treatment of Patients With Primary Immunodeficiencies

Primary Immunodeficiency Diseases (PID)

Russian Federation
ADMA Biologics, Inc.

Recruiting

An Open Label, Multicenter Study to Evaluate the Pharmacokinetics, Efficacy and Safety of ASCENIV™ (IGIV) in Pediatric Subjects With Primary Immunodeficiency Diseases (PIDD)

Primary Immune Deficiency

United States
Octapharma

Recruiting

Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases

Primary Immune Deficiency

United States, Germany, Italy, Poland, Slovakia, Ukraine, Hungary
Baxalta now part of Shire

Completed

Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subjects

Primary Immunodeficiency Diseases (PID)

United States
Baxalta now part of Shire

Completed

Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously

Primary Immunodeficiency Diseases (PID)

United States

Clinical Trials on Immunologic Disease

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations